COLUMBIA, Md.--(BUSINESS WIRE)--Osiris Therapeutics, Inc. (NASDAQ:OSIR) today announced the treatment of the first patient in a Phase II clinical trial evaluating Prochymal for the treatment of heart attacks. The first patient, a 58-year old man, was treated at the Heart Hospital of Austin, Texas.
